Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all trial steps are most likely to undergo a biopsy at the end of the trial, according to recent research.
Researchers found that men who aren't well educated about prostate cancer have more difficulty making decisions.
Men who eat more than 10 portions of tomatoes each week have an 18% lower risk of developing prostate cancer.
A calculator to help men and their doctors assess the risk of prostate cancer has had a major upgrade to enhance men's and their physicians' understanding of a man's risk of prostate cancer.
Men without prostate cancer taking part in the trial who participate in other aspects are most likely to undergo a challenging biopsy.
Prostate-specific antigen (PSA) screening is associated with a lasting reduction in prostate cancer mortality, according to a study published online.
A genomic tool can help doctors and patients make a more informed decision on the need for radiation therapy after surgery for prostate cancer.
Men with diagnosed depressive disorders are less likely to pursue definitive treatment options for prostate cancer and more likely to have poorer outcomes.
Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study.
Although their lives eventually return to normal after treatment, some men have to cope with lingering effects of their treatment that affects their libido or sexual function. Daniel Watter, EdD, offers guidance tips to share with patients who are surviving prostate cancer that can help them through the recovery process.
Two independent trials have validated the performance of an epigenetic test that could provide physicians with a better tool to help eliminate unnecessary repeat prostate biopsies.
A study of people who were adopted identified genetics as the dominant risk factor in familial breast, prostate, and colorectal cancers.
Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer, according to a new study.
A research team from Japan found that 16-core biopsy has a slightly higher detection rate than 12-core biopsy.
Researchers found that cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.
Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.
Results of a new study show that robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years.
Vasectomy is associated with an increased incidence of prostate cancer overall during extended follow-up, with an elevated risk seen for high-grade and lethal cancer.
Depressed men with a diagnosis of intermediate- or high-risk prostate cancer have worse overall outcomes.
Physicians who diagnosed low-risk prostate cancer had more influence over the decision to enter active surveillance than did the disease characteristics, according to a case review.
Key genetic variants may affect how cancer patients respond to radiation treatments, according to a new study.
Researchers searching for a target that would interfere with cancer metastasis identified a new suppressor of metastasis that may lead toward the development of more effective treatments for prostate cancer and other malignant solid tumors.
Hot flashes are a common side effect of menopausal changes experienced by women; however, they can also be a hormone-related effect experienced by men with prostate cancer.
A new study is suggesting a different approach to treating prostate cancer. Researchers at Comprehensive Cancer Centers of Nevada conducted a study in which 790 men with advanced stages of prostate cancer received early chemotherapy.
The loss of the p62 protein in tumor cells and the surrounding tissue can enhance the growth and progression of tumors, according to research from Sanford Burnham Medical Research Institute. The findings add to the acknowledgement that the stroma is an integral part of cancer initiation, growth, and expansion.
Specialists who treat prostate cancer agree that active surveillance is an effective option for patients with low-risk prostate cancer; however, most are more likely to recommend the treatment provided by their own specialties.
In an international randomized phase III clinical trial, the hormone therapy enzalutamide extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy.
Although most prostate cancer specialists believe active surveillance to be effective and underused, fewer endorse active surveillance than other therapies for low-risk prostate cancer.
A groundbreaking molecular imaging agent has been developed to help clinicians find as much prostate cancer as possible and determine whether it is responding favorably or not.
Specialists who treat prostate cancer agree that active surveillance is an effective option—yet according to a study most don't recommend it when appropriate for their own patients.
A study from the University of Iowa examined the charge for prostate cancer surgery at 100 hospital all over the United States, and the results showed widely different prices.
Gonadotropin-releasing hormone-I (GnRH-I) has attracted strong attention as a hormonal therapeutic tool, particularly for androgen-dependent prostate cancer patients. Here, we investigated the effect of SN09-2 on the growth of PC3 prostate cancer cells.
Male patients with prostate cancer, and patients with other genitourinary cancers, need information on how their cancer and its treatment will affect their life.
Improved diagnosis and management of prostate cancer could result from research that has discovered that seminal fluid contains biomarkers for the disease.
New guidelines have been developed for clinical follow-up care for prostate cancer survivors. Issues addressed include health promotion, surveillance for recurrence, and new primaries.
The American Cancer Society released a set of guidelines addressing the long-term primary care for survivors of prostate cancer. The guidelines outline follow-up care, monitoring for recurrence, and screening for secondary primary cancers. They also reiterate the need to educate survivors about physical exercise and smoking cessation.
An enzyme commonly used as a target for antidepressants may also promote prostate cancer growth, according to an international team of scientists.
A new screening technique, MR fusion guided prostate biopsy, holds promise for increased prostate cancer detection.
The Prolaris test distinguished newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower risk disease.
Improved diagnosis and management of prostate cancer could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.
Researchers have developed a new technique to combat metastatic prostate cancer (which is called castration-resistant), which could delay the start of chemotherapy.
Many people are unaware that prostate cancer may sometimes be transmitted sexually.
Circumcision appears to confer a protective effect against the development of prostate cancer, according to research published online.
There's new evidence that certain drugs used to treat depression might also help stop the growth of prostate cancer.
Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study.
Claims of not receiving proper informed consent and clinical performance are the main issues that arise in radical prostatectomy malpractice lawsuits.
Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.
The site of metastatic tumors powerfully predicts overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC), confirms a meta-analysis presented at the 2014 American Society of Clinical Oncology Annual Meeting.
Treating older men with early stage prostate cancer who also have other serious health problems with aggressive therapies does not help them live longer and, in fact, can be detrimental.
A commercial test designed to rule out the presence of genetic biomarkers of prostate cancer could exclude the need for repeat prostate biopsies in many patients.
Targeted prostate biopsy using multi-parametric magnetic resonance imaging-ultrasound fusion may lead to reclassification of prostate cancer that was initially diagnosed as low-risk, according to research.
Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in men who underwent their first prostate biopsy because of abnormal PSA test and/or DRE results.
For men with early-stage prostate cancer, the cancer-specific survival benefit associated with aggressive prostate cancer treatment is reduced with increasing comorbidity, according to a study.
A novel noninvasive technique can detect prostate cancer using an electronic nose.
A new gene expression analysis approach for identifying cancer genes challenges the current paradigm of microarray data analysis.
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients.
For men with low-risk prostate cancer, low levels of testosterone may indicate a worsening of their disease, concluded a new study.
The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer.
The ChemPro 100-electronic nose can discriminate prostate cancer from benign prostatic hyperplasia using urine headspace, according to a study.
Men under active surveillance for prostate cancer who have reductions in testosterone levels may be at increased risk for disease reclassification, according to research.
A protein called BET bromodomain protein 4 binds to the androgen receptor downstream of where current therapies work, where it targets androgen receptor signaling. This new study suggests a way to block hormones, since prostate cancer that becomes resistant to current treatments might remain sensitive to a drug that targets BET bromodomain proteins.
Sexual dysfunction is a common and distressing side effect of prostate cancer treatment. Two new reports from randomized clinical trials offer mixed results for adjuvant pharmacotherapy intended to prevent erectile dysfunction in men undergoing radiotherapy for prostate cancer.
Men with prostate cancer that is small and confined to the prostate gland but at risk of growing, do better if they are treated with radiotherapy combined with androgen deprivation therapy.
Severe vitamin D deficiency linked with higher grade and stage of prostate tumors, according to research.
Multiparametric MRI is highly accurate for the detection of prostate cancer in patients with clinically low-risk cancer; accuracy is highest with larger cancer volume and higher Gleason grade.
Ninety-one men and 100 caregivers shared their thoughts on what worries them most when advanced prostate cancer becomes a way of life.
Men with metastatic, castration-resistant prostate cancer who started treatment with enzalutamide and had the molecule AR-V7 present in CTCs obtained prior to treatment had a worse response to enzalutamide.
The presence of chronic inflammation in benign prostate tissue samples is associated with prostate cancer, especially high-grade disease, according to a study.
Adherence to established prostate cancer quality of care measures is frequently low, with considerable regional variation.
In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.
The PROCEDE 500 study demonstrated that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.
Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).
A new study found substantial long-term reduction in mortality for men with localized prostate cancer who undergo a radical prostatectomy.
For localized prostate cancer, primary androgen-deprivation therapy does not prolong survival for the majority of men who have not received treatment with curative intent.
Although patients with prostate cancer endorse multiple sources of information, they report greatest satisfaction with information from the treating physician about patient outcomes.
Risk of long-term mortality for those that undergo surgical treatment is lower, compared with men who choose watchful waiting.
Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.
The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.
A new study examined how a genetic mutation in untreated patients is linked to aggressive prostate cancer later in life.
Three-dimensional biopsies find more prostate cancers, particularly in the anterior regions, than those guided by ultrasound, according to a new clinical study.
New evidence lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis.
Men with prostate cancer on active surveillance should be informed of the risk of complications linked to repeated biopsies.
Results from PROCEDE 500, a clinical utility study with the Prolaris test, demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.
Men who walked at a fast pace prior to a prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes.
Two beneficial treatment approaches are available for metastatic and locally advanced prostate cancer, according to two studies presented in advance of ASCO's annual Genitourinary Cancers Symposium.
Soy and soy isoflavones are alleviating skin and lung toxicities from thoracic radiotherapy in preclinical study models; however, researchers stress the need for further studies.
Additional predictors guide selection of patients with prostate cancer for active surveillance programs.
Brisk walking before prostate cancer diagnosis has been associated with more regularly-shaped blood vessels.
Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated.
After adjusting for potential confounders, men with high levels of 6-sulfatoxymelatonin demonstrated a significantly lower prostate cancer risk.
The methods used to anesthetize patients with prostate cancer and control pain due to surgical resection of the prostate glands for adenocarcinoma may affect patients' long-term cancer outcomes, a study has found.
In vivo BPA exposure has been tied to increased incidence of prostate intraepithelial neoplasia and adenocarcinoma.
A cell-surface protein called CD151 may serve as a biomarker that accurately predicts which patients with prostate cancer are likely to experience metastasis or recurrence.
With a deluge of promising new treatments for advanced prostate cancer, a new model of care is needed that emphasizes collaboration between urology and medical oncology clinicians.
Supplementing general anesthesia (GA) with neuraxial anesthesia during prostate cancer surgery is associated with improved oncological outcomes compared with GA alone.
Framework for optimizing CRPC treatment should involve joint management by both a urologist and a medical oncologist.
The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.
Men with prostate cancer who take the cholesterol-lowering drugs known as statins are significantly less likely to die from their cancer than men who do not take such medication, according to a new study.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|